Table 1 Clinicopathologic variables and the expression of FAM83H and ZNF16 in gallbladder carcinomas
Characteristics | No. | nuclear FAM83H | cytoplasmic FAM83H | nuclear ZNF16 | cytoplasmic ZNF16 | ||||
|---|---|---|---|---|---|---|---|---|---|
Positive | p | Positive | p | Positive | p | Positive | p | ||
Age, years | |||||||||
< 65 | 55 | 23 (42%) | 0.296 | 15 (27%) | 0.241 | 30 (55%) | 0.573 | 16 (29%) | 0.046 |
≥ 65 | 50 | 26 (52%) | 19 (38%) | 30 (60%) | 24 (48%) | ||||
Sex | |||||||||
Male | 55 | 26 (47%) | 0.896 | 19 (35%) | 0.619 | 31 (56%) | 0.866 | 22 (40%) | 0.673 |
Female | 50 | 23 (46%) | 15 (30%) | 29 (58%) | 18 (36%) | ||||
CEA | |||||||||
Normal | 86 | 39 (45%) | 0.565 | 27 (31%) | 0.646 | 50 (58%) | 0.661 | 35 (41%) | 0.243 |
Elevated | 19 | 10 (53%) | 7 (37%) | 10 (53%) | 5 (26%) | ||||
CA19–9 | |||||||||
Normal | 71 | 30 (42%) | 0.190 | 23 (32%) | 0.997 | 36 (51%) | 0.054 | 25 (35%) | 0.379 |
Elevated | 34 | 19 (56%) | 11 (32%) | 24 (71%) | 15 (44%) | ||||
TNM stage | |||||||||
I | 25 | 7 (28%) | 0.122 | 5 (20%) | 0.040 | 8 (32%) | 0.028 | 3 (12%) | 0.003 |
II | 37 | 19 (51%) | 11 (30%) | 23 (62%) | 20 (54%) | ||||
III | 31 | 15 (48%) | 10 (32%) | 20 (65%) | 10 (32%) | ||||
IV | 12 | 8 (67%) | 8 (67%) | 9 (75%) | 7 (58%) | ||||
T category | |||||||||
T1 | 26 | 7 (27%) | 0.101 | 5 (19%) | 0.071 | 8 (31%) | 0.014 | 3 (12%) | < 0.001 |
T2 | 50 | 26 (52%) | 15 (30%) | 31 (62%) | 27 (54%) | ||||
T3 | 25 | 13 (52%) | 11 (44%) | 18 (72%) | 7 (28%) | ||||
T4 | 4 | 3 (75%) | 3 (75%) | 4 (100%) | 3 (75%) | ||||
LN metastasis | |||||||||
Absence | 79 | 34 (43%) | 0.194 | 25 (32%) | 0.779 | 43 (54%) | 0.328 | 32 (41%) | 0.375 |
Presence | 26 | 15 (58%) | 9 (35%) | 17 (65%) | 8 (31%) | ||||
Distant metastasis | |||||||||
Absence | 98 | 45 (46%) | 0.565 | 29 (30%) | 0.022 | 54 (55%) | 0.114 | 36 (37%) | 0.283 |
Presence | 7 | 4 (57%) | 5 (71%) | 6 (86%) | 4 (57%) | ||||
Lymphovascular invasion | |||||||||
Absence | 95 | 44 (46%) | 0.824 | 29 (31%) | 0.211 | 52 (55%) | 0.125 | 38 (40%) | 0.215 |
Presence | 10 | 5 (50%) | 5 (50%) | 8 (80%) | 2 (20%) | ||||
Histologic type | |||||||||
Adenocarcinoma NOS | 101 | 48 (48%) | 0.571 | 32 (32%) | 0.348 | 58 (57%) | 0.485 | 38 (38%) | 0.435 |
Adenosquamous carcinoma | 3 | 1 (33%) | 2 (67%) | 2 (67%) | 2 (67%) | ||||
Squamous cell carcinoma NOS | 1 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||||
Histologic grade | |||||||||
Low | 43 | 15 (35%) | 0.044 | 7 (16%) | 0.003 | 15 (35%) | < 0.001 | 12 (28%) | 0.073 |
High | 62 | 34 (55%) | 27 (44%) | 45 (73%) | 28 (45%) | ||||
cytoplasmic ZNF16 | |||||||||
Negative | 65 | 26 (40%) | 0.081 | 25 (23%) | 0.009 | 28 (43%) | < 0.001 | ||
Positive | 40 | 23 (58%) | 19 (48%) | 32 (80%) | |||||
nuclear ZNF16 | |||||||||
Negative | 45 | 13 (29%) | 0.002 | 9 (20%) | 0.019 | ||||
Positive | 60 | 36 (60%) | 25 (42%) | ||||||
cytoplasmic FAM83H | |||||||||
Negative | 71 | 24 (34%) | < 0.001 | ||||||
Positive | 34 | 25 (74%) | |||||||